Startup profile for Commit Biologics: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Commit Biologics funding, valuation and investors

Aarhus University spinout designing antibodies that enlist the complement immune system to eliminate selected cancer or autoimmune-disease cells.

Verified company research · funding, investors and latest developments

Keep track of Commit Biologics

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed final close (aggregate including older tranches)

€54M total Seed; incremental final-close proceeds undisclosed · November 17, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed · Copenhagen and Aarhus, Denmark

Investors in latest funding

Lead: Ackermans & van Haaren

Other: AbbVie Ventures , M Ventures , Novo Holdings , Bioqube Ventures , Korys

Sources: latest funding · commitbio.com Last verified: 2026-11-18

Overview

Commit Biologics is a Danish biotech spinout of Aarhus University developing Bispecific Complement Engager (BiCE) antibodies. Its approach fuses a disease-cell-targeting antibody arm with a C1q recruitment domain, attempting to direct the classical complement pathway against targeted cells without relying on functional T cells.

Lead program COM002 was nominated November 12, 2026 for advancement through IND-enabling studies and clinical filing; the company expects first human dosing in early 2028, not a completed trial or approved product.

In a company-reported November 2025 non-human-primate study, an earlier BiCE antibody induced sustained B-cell depletion after one dose without observed treatment-related safety findings; animal results cannot establish human efficacy or safety.

The November 17, 2026 $60M/€54M announcement finalizes a Seed financing assembled in stages: €16M announced May 9, 2024 by Novo Holdings/Bioqube, plus an additional €5.5M from Korys announced January 28, 2025 (total then €21.5M), followed by later commitments to a €54M total. The exact incremental amount invested in the final closing is not separately disclosed by the company's own announcement.

Ackermans & van Haaren led the final close; AbbVie Ventures and M Ventures joined, and existing Novo Holdings, Bioqube Ventures and Korys participated. This is an investigational therapeutic platform aimed at future biotech partnering and medicines, not a product available to clinicians today. Sales, valuation, pricing and licensing terms are undisclosed.

Why Commit Biologics is interesting

November 17, 2026 was a €54M total Seed final close, not €54M of additional November capital. COM002 is preclinical; first patient dosing is targeted for early 2028 and clinical efficacy is unproven.

Product & use cases

Research/development path: select disease-associated antigen; engineer bispecific IgG-like antibody for that target plus complement C1q; measure binding and cell killing in preclinical models; test on-target versus off-target complement toxicity, manufacturing and pharmacokinetics; submit an investigational drug application after IND-enabling studies; test safety/dose in humans before any efficacy conclusions. COM002 candidate nomination is not approval. Complement activity and tissue distribution may not reproduce across species; complement-related inflammation or off-target killing remain material risks.

  • Preclinical targeted B-cell depletion using complement activation without dependence on cytotoxic T cells.
  • Potential future immunotherapy for selected lymphoma and autoimmune conditions, contingent on human trials.
  • Biotech partner diligence: compare complement engagement, T-cell bispecifics, CAR-T, anti-CD20 and complement inhibition as mechanistically distinct alternatives.

Key facts

  • €54M total Seed financing at November 17, 2026 final close; this amount includes earlier €16M and €5.5M Seed tranches.
  • COM002 first candidate nominated November 12, 2026, first patient dosing planned early 2028.
  • 2025 primate proof-of-concept is company-reported preclinical data, not demonstrated clinical benefit.

Funding history (newest first)

Seed final close (aggregate including older tranches)

2026-11-17 €54M total Seed; incremental final-close proceeds undisclosed
  • Ackermans & van Haaren (lead)
  • AbbVie Ventures (participant)
  • M Ventures (participant)
  • Novo Holdings (participant)
  • Bioqube Ventures (participant)
  • Korys (participant)

Source: Read source · commitbio.com

Seed extension (historical incremental tranche)

2025-01-28 €5.5M incremental; €21.5M Seed total at that date
  • Korys (lead)

Source: Read source · commitbio.com

Seed first disclosed tranche (historical)

2024-05-09 €16M (part of €54M cumulative Seed)

Source: Read source · commitbio.com

Competitive landscape

Edge: Proposed complement targeting via C1q may offer T-cell-independent depletion in tissues where T-cell activity is limited; claim remains preclinical and is not a proven clinical superiority.

Disconfirming tests are whether C1q recruitment remains selective in diseased human tissue, whether complement consumption and inflammatory toxicity can be controlled, and whether the candidate improves efficacy relative to mature antibody, bispecific or cellular regimens.

  • Conventional anti-CD20 antibodies alternative

    Existing B-cell depletion approaches with validated clinical use in some indications, but different pharmacology.

  • T-cell engaging bispecific antibodies alternative

    Redirect T cells rather than complement, with different dependency and safety profile.

  • CAR-T cell therapies alternative

    Engineered T-cell treatment, often complex to manufacture and administer.

  • Complement inhibitors adjacent

    Block complement activity for inflammatory disorders rather than enlist complement for target-cell elimination.

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Commit Biologics

Practical answers founders, operators, and investors typically search for.

No. Its November 17 announcement describes a €54M total Seed financing final close that incorporates earlier disclosed tranches. The size of the new final-close installment was not separately disclosed.
No. As of November 18, 2026, COM002 has been selected for development and is undergoing preclinical IND-enabling work, with first dosing planned for early 2028.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.